Merlin neutralizes the inhibitory effect of Mdm2 on p53

被引:54
作者
Kim, H
Kwak, NJ
Lee, JY
Choi, BH
Lim, Y
Ko, YJ
Kim, YH
Huh, PW
Lee, KH
Rha, HK
Wang, YP
机构
[1] Catholic Univ Korea, Neurosci Genome Res Ctr, Seoul 137701, South Korea
[2] Catholic Univ Korea, Dept Occupat & Environm Med, Seoul 137701, South Korea
[3] Catholic Univ Korea, Dept Pharmacol, Seoul 137701, South Korea
[4] Catholic Univ Korea, Dept Thorac & Cardiovasc Surg, Seoul 137701, South Korea
关键词
D O I
10.1074/jbc.M305526200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The stability of p53 tumor suppressor is regulated by Mdm2 via the ubiquitination and proteasome-mediated proteolysis pathway. The c-Abl and PTEN tumor suppressors are known to stabilize p53 by blocking the Mdm2-mediated p53 degradation. This study investigated the correlation between p53 and merlin, a neurofibromatosis 2 ( NF2)-related tumor suppressor, in association with the Mdm2 function. The results showed that merlin increased the p53 stability by inhibiting the Mdm2-mediated degradation of p53, which accompanied the increase in the p53-dependent transcriptional activity. The stabilization of p53 by merlin appeared to be accomplished through Mdm2 degradation, and the N-terminal region of merlin was responsible for this novel activity. This study also showed that overexpression of merlin-induced apoptosis of cells depending preferentially on p53 in response to the serum starvation or a chemotherapeutic agent. These results suggest that merlin could be a positive regulator of p53 in terms of tumor suppressor activity, and provide the promising therapeutic means for treating tumors with non-functional merlin or Mdm2 overexpression.
引用
收藏
页码:7812 / 7818
页数:7
相关论文
共 39 条
[1]   Mechanisms of p53-mediated apoptosis [J].
Bates, S ;
Vousden, KH .
CELLULAR AND MOLECULAR LIFE SCIENCES, 1999, 55 (01) :28-37
[2]   MAPPING OF THE P53 AND MDM-2 INTERACTION DOMAINS [J].
CHEN, JD ;
MARECHAL, V ;
LEVINE, AJ .
MOLECULAR AND CELLULAR BIOLOGY, 1993, 13 (07) :4107-4114
[3]   A GENETIC-STUDY OF TYPE-2 NEUROFIBROMATOSIS IN THE UNITED-KINGDOM .1. PREVALENCE, MUTATION-RATE, FITNESS, AND CONFIRMATION OF MATERNAL TRANSMISSION EFFECT ON SEVERITY [J].
EVANS, DGR ;
HUSON, SM ;
DONNAI, D ;
NEARY, W ;
BLAIR, V ;
TEARE, D ;
NEWTON, V ;
STRACHAN, T ;
RAMSDEN, R ;
HARRIS, R .
JOURNAL OF MEDICAL GENETICS, 1992, 29 (12) :841-846
[4]   TUMORIGENIC POTENTIAL ASSOCIATED WITH ENHANCED EXPRESSION OF A GENE THAT IS AMPLIFIED IN A MOUSE-TUMOR CELL-LINE [J].
FAKHARZADEH, SS ;
TRUSKO, SP ;
GEORGE, DL .
EMBO JOURNAL, 1991, 10 (06) :1565-1569
[5]   THE MDM-2 ONCOGENE CAN OVERCOME WILD-TYPE P53 SUPPRESSION OF TRANSFORMED-CELL GROWTH [J].
FINLAY, CA .
MOLECULAR AND CELLULAR BIOLOGY, 1993, 13 (01) :301-306
[6]   Functions of the MDM2 oncoprotein [J].
Freedman, DA ;
Wu, L ;
Levine, AJ .
CELLULAR AND MOLECULAR LIFE SCIENCES, 1999, 55 (01) :96-107
[7]  
Giovannini M, 2000, GENE DEV, V14, P1617
[8]   Tyrosine phosphorylation of Mdm2 by c-Abl: implications for p53 regulation [J].
Goldberg, Z ;
Vogt Sionov, R ;
Berger, M ;
Zwang, Y ;
Perets, R ;
Van Etten, RA ;
Oren, M ;
Taya, Y ;
Haupt, Y .
EMBO JOURNAL, 2002, 21 (14) :3715-3727
[9]   p53 in growth control and neoplasia [J].
Gottlieb, TM ;
Oren, M .
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 1996, 1287 (2-3) :77-102
[10]   p300/MDM2 complexes participate in MDM2-mediated p53 degradation [J].
Grossman, SR ;
Perez, M ;
Kung, AL ;
Joseph, M ;
Mansur, C ;
Xiao, ZX ;
Kumar, S ;
Howley, PM ;
Livingston, DM .
MOLECULAR CELL, 1998, 2 (04) :405-415